TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) Short Interest Update

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 11,100 shares, a growth of 37.0% from the March 15th total of 8,100 shares. Based on an average daily volume of 9,300 shares, the short-interest ratio is presently 1.2 days.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Clear Street LLC acquired a new stake in shares of TriSalus Life Sciences in the fourth quarter valued at approximately $60,000. Context Capital Management LLC acquired a new stake in shares of TriSalus Life Sciences in the third quarter valued at approximately $27,000. Shaolin Capital Management LLC acquired a new stake in shares of TriSalus Life Sciences in the third quarter valued at approximately $29,000. Wolverine Asset Management LLC acquired a new stake in shares of TriSalus Life Sciences in the fourth quarter valued at approximately $123,000. Finally, Walleye Capital LLC acquired a new stake in shares of TriSalus Life Sciences in the third quarter valued at approximately $40,000.

TriSalus Life Sciences Stock Performance

NASDAQ TLSIW traded down $0.01 during trading hours on Friday, hitting $0.99. 2,138 shares of the company traded hands, compared to its average volume of 11,750. The business’s 50-day moving average is $1.03 and its 200-day moving average is $0.73. TriSalus Life Sciences has a twelve month low of $0.02 and a twelve month high of $1.35.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors.